Clincosm LogoSign in Get a demo

Non-Hodgkin Lymphoma

Showing 26 - 50 of 213
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma Trial in Australia, United States (BGB-16673)

Recruiting
  • B-cell Malignancy
  • +8 more
  • Phoenix, Arizona
  • +14 more
Jan 17, 2023

Non-Hodgkin Lymphoma Trial in Columbus (Biospecimen Collection, Computed Tomography, Positron Emission Tomography)

Recruiting
  • Non-Hodgkin Lymphoma
  • Biospecimen Collection
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Jan 13, 2023

Non-hodgkin Lymphoma Trial in Tianjin (GNC-038)

Recruiting
  • Non-hodgkin Lymphoma
  • Hefei, Anhui, China
  • +9 more
Jan 12, 2023

NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)

Not yet recruiting
  • NK/T Cell Lymphoma
  • +2 more
  • Guangzhou, Guangdong, China
  • +1 more
Jan 12, 2023

Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma Trial in United States (NKTR-255 at 1.5 µg/kg, NKTR-255

Recruiting
  • Non-Hodgkin Lymphoma
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma
  • NKTR-255 at 1.5 µg/kg
  • +3 more
  • La Jolla, California
  • +26 more
Jan 10, 2023

Non-Hodgkin Lymphoma Trial in Worldwide (Tisagenlecleucel after optional bridging and lymphodepleting chemo, Platinum-based

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
  • Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
  • La Jolla, California
  • +66 more
Jan 6, 2023

Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma Trial in San Antonio (WTX-330)

Recruiting
  • Advanced or Metastatic Solid Tumors
  • Non-Hodgkin Lymphoma
  • San Antonio, Texas
    NEXT Oncology
Jan 6, 2023

Acute Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma Trial (3D189)

Recruiting
  • Acute Leukemia
  • +3 more
  • 3D189
  • Guangzhou, Guangdong, China
  • +3 more
Jan 2, 2023

Non-Hodgkin Lymphoma, Follicular Lymphoma, DLBCL Trial in Australia, Korea, Republic of, United States (IGM-2323)

Recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • Duarte, California
  • +23 more
Dec 28, 2022

Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Trial in Aurora, Seattle (drug, procedure,

Active, not recruiting
  • Acute Biphenotypic Leukemia
  • +18 more
  • Aurora, Colorado
  • +2 more
Dec 28, 2022

Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in France, Germany, United States (Odronextamab multiple dose levels)

Recruiting
  • Non-Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Odronextamab multiple dose levels
  • Orange, California
  • +20 more
Dec 14, 2022

Solid Tumor, Adult, Non-hodgkin Lymphoma, Hodgkin Lymphoma Trial in India (AUR105)

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • Vadodara, Gujarat, India
  • +6 more
Dec 14, 2022

B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy Trial (CTX112)

Not yet recruiting
  • B-cell Lymphoma
  • +7 more
  • CTX112
  • (no location specified)
Dec 12, 2022

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Trial in

Active, not recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +11 more
  • Duarte, California
    City of Hope Medical Center
Dec 8, 2022

B-Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Worldwide (Glofitamab, Obinutuzumab (G), Rituximab (R))

Active, not recruiting
  • B-Cell Lymphoma
  • Non-Hodgkin Lymphoma
  • Birmingham, Alabama
  • +23 more
Dec 2, 2022

Non-Hodgkin Lymphoma Trial in United States (GDA-201)

Recruiting
  • Non-Hodgkin Lymphoma
  • Maywood, Illinois
  • +4 more
Nov 30, 2022

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in United States (JCAR017 (lisocabtagene

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • JCAR017 (lisocabtagene maraleucel) single-dose schedule
  • JCAR017 (lisocabtagene maraleucel) 2-dose schedule
  • Birmingham, Alabama
  • +24 more
Nov 21, 2022

CB-Long-Term Safety Study (CB-LTSS)

Enrolling by invitation
  • Lymphoma, Non-Hodgkin
  • +7 more
  • Allogeneic CAR-T therapy
  • Irvine, California
  • +3 more
Nov 18, 2022

Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia Trial in United States (drug, radiation,

Recruiting
  • Acute Erythroid Leukemia
  • +10 more
  • San Francisco, California
  • +5 more
Nov 1, 2022

Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical

Completed
  • Multiple Myeloma
  • +7 more
  • Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Nov 2, 2022

B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (AS-1763)

Not yet recruiting
  • B-cell Malignancy
  • +7 more
  • (no location specified)
Oct 26, 2022

Solid Tumor, Non-Hodgkin Lymphoma Trial in Guangzhou, Shanghai (ADG106)

Active, not recruiting
  • Solid Tumor
  • Non-Hodgkin Lymphoma
  • Guangzhou, Guangdong, China
  • +1 more
Oct 15, 2022

Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)

Not yet recruiting
  • Non-Hodgkin Lymphoma
  • Cologne, Germany
    University of Cologne
Oct 14, 2022

Anthracycline-induced Cardiac Toxicity, Non-Hodgkin Lymphoma Trial in Worldwide (RIPC, Simulated RIPC (Sham))

Recruiting
  • Anthracycline-induced Cardiac Toxicity
  • Non-Hodgkin Lymphoma
  • RIPC
  • Simulated RIPC (Sham)
  • Aarhus, Denmark
  • +18 more
Oct 5, 2022

Melanoma, NSCLC, Breast Cancer Trial in United States (CDX-1140, CDX-301, Pembrolizumab)

Completed
  • Melanoma
  • +25 more
  • Scottsdale, Arizona
  • +10 more
Sep 27, 2022